Clinical Trial Update: A Safety Study of Lactobacillus Reuteri BGP-014 in Patients With Ulcerative Colitis [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports the completion of a Phase 1/2 safety study of Lactobacillus reuteri BGP-014 in patients with Ulcerative Colitis. The trial is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Lactobacillus reuteri BGP-014 (Lactobacillus reuteri)

Snippet

Sponsor: BioGaia Pharma AB | Conditions: Ulcerative Colitis | Phase 1, Phase 2 | Status: COMPLETED